Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Centralized Clinical Trial Imaging Data Management: Practical Guidance from a Comprehensive Cancer Center's Experience.

Lee B, Abbott A, Davidson S, Syrkin L, LeFever G, Van den Abbeele AD.

J Digit Imaging. 2019 Oct;32(5):849-854. doi: 10.1007/s10278-018-0161-0.

PMID:
30564956
2.

Guidance on 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division.

Abbott A, Sakellis CG, Andersen E, Kuzuhara Y, Gilbert L, Boyle K, Kulke MH, Chan JA, Jacene HA, Van den Abbeele AD.

J Nucl Med Technol. 2018 Sep;46(3):237-244. doi: 10.2967/jnmt.118.209148. Epub 2018 Aug 3.

3.

Development and validation of a new MRI simulation technique that can reliably estimate optimal in vivo scanning parameters in a glioblastoma murine model.

Protti A, Jones KL, Bonal DM, Qin L, Politi LS, Kravets S, Nguyen QD, Van den Abbeele AD.

PLoS One. 2018 Jul 23;13(7):e0200611. doi: 10.1371/journal.pone.0200611. eCollection 2018.

4.

Effects of hyperglycemia on fluorine-18-fluorodeoxyglucose biodistribution in a large oncology clinical practice.

Rosica D, Cheng SC, Hudson M, Sakellis C, Van den Abbeele AD, Kim CK, Jacene HA.

Nucl Med Commun. 2018 May;39(5):417-422. doi: 10.1097/MNM.0000000000000829.

PMID:
29629997
5.

LesionTracker: Extensible Open-Source Zero-Footprint Web Viewer for Cancer Imaging Research and Clinical Trials.

Urban T, Ziegler E, Lewis R, Hafey C, Sadow C, Van den Abbeele AD, Harris GJ.

Cancer Res. 2017 Nov 1;77(21):e119-e122. doi: 10.1158/0008-5472.CAN-17-0334.

6.

Yield of bone scintigraphy for the detection of metastatic disease in treatment-naive prostate cancer: a systematic review and meta-analysis.

Suh CH, Shinagare AB, Westenfield AM, Ramaiya NH, Van den Abbeele AD, Kim KW.

Clin Radiol. 2018 Feb;73(2):158-167. doi: 10.1016/j.crad.2017.08.004. Epub 2017 Sep 25. Review.

PMID:
28958581
7.

Surveillance Imaging in Patients With Endometrial Cancer in First Remission.

Alabed YZ, Cheng SC, Mudge C, Sakellis C, Van den Abbeele AD, Campos SM, Jacene HA.

Curr Probl Diagn Radiol. 2018 Sep;47(5):311-316. doi: 10.1067/j.cpradiol.2017.08.003. Epub 2017 Aug 24.

PMID:
28917433
8.

Immune Modulation Therapy and Imaging: Workshop Report.

Shields AF, Jacobs PM, Sznol M, Graham MM, Germain RN, Lum LG, Jaffee EM, de Vries EGE, Nimmagadda S, Van den Abbeele AD, Leung DK, Wu AM, Sharon E, Shankar LK.

J Nucl Med. 2018 Mar;59(3):410-417. doi: 10.2967/jnumed.117.195610. Epub 2017 Aug 17.

9.

Cancer Imaging Fellowship Training: Utility and Added Value in the Modern Era.

Krajewski KM, Howard SA, Shinagare AB, Van den Abbeele AD, Fennessy FM.

J Am Coll Radiol. 2017 Oct;14(10):1345-1348. doi: 10.1016/j.jacr.2017.06.005. Epub 2017 Jul 8. No abstract available.

PMID:
28697959
10.

Prognostic significance of supradiaphragmatic lymph nodes at initial presentation in patients with stage III high-grade serous ovarian cancer.

McIntosh LJ, O'Neill AC, Bhanusupriya S, Matalon SA, Van den Abbeele AD, Ramaiya NH, Shinagare AB.

Abdom Radiol (NY). 2017 Oct;42(10):2513-2520. doi: 10.1007/s00261-017-1158-8.

PMID:
28429056
11.

Ovarian Cancer: An Evidence-Based, Easy-to-Use Prediction Rule to Optimize the Use of Follow-up Chest CT.

Shinagare AB, Suh CH, Kim KW, Somarouthu B, Van den Abbeele AD, Ramaiya NH.

J Am Coll Radiol. 2017 Apr;14(4):499-508. doi: 10.1016/j.jacr.2016.08.010. Epub 2016 Oct 6.

PMID:
27720583
12.

Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma.

O'Neill AF, Qin L, Wen PY, de Groot JF, Van den Abbeele AD, Yap JT.

J Neurooncol. 2016 Dec;130(3):495-503. Epub 2016 Aug 30.

PMID:
27576699
13.

Patterns and Prognostic Importance of Hepatic Involvement in Patients with Serous Ovarian Cancer: A Single-Institution Experience with 244 Patients.

O'Neill AC, Somarouthu B, Tirumani SH, Braschi-Amirfarzan M, Van den Abbeele AD, Ramaiya NH, Shinagare AB.

Radiology. 2017 Jan;282(1):160-170. doi: 10.1148/radiol.2016152595. Epub 2016 Aug 1.

PMID:
27479640
14.

Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.

Ben-Ami E, Barysauskas CM, von Mehren M, Heinrich MC, Corless CL, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Yap JT, Van den Abbeele AD, Solomon SM, Fletcher JA, Demetri GD, George S.

Ann Oncol. 2016 Sep;27(9):1794-9. doi: 10.1093/annonc/mdw228. Epub 2016 Jul 1.

15.

Cancer Imaging at the Crossroads of Precision Medicine: Perspective From an Academic Imaging Department in a Comprehensive Cancer Center.

Van den Abbeele AD, Krajewski KM, Tirumani SH, Fennessy FM, DiPiro PJ, Nguyen QD, Harris GJ, Jacene HA, Lefever G, Ramaiya NH.

J Am Coll Radiol. 2016 Apr;13(4):365-71. doi: 10.1016/j.jacr.2015.11.002. Epub 2016 Jan 14.

PMID:
26774886
16.

Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.

Reardon DA, Gokhale PC, Klein SR, Ligon KL, Rodig SJ, Ramkissoon SH, Jones KL, Conway AS, Liao X, Zhou J, Wen PY, Van Den Abbeele AD, Hodi FS, Qin L, Kohl NE, Sharpe AH, Dranoff G, Freeman GJ.

Cancer Immunol Res. 2016 Feb;4(2):124-35. doi: 10.1158/2326-6066.CIR-15-0151. Epub 2015 Nov 6.

17.

Pancreatitis Secondary to Anti-Programmed Death Receptor 1 Immunotherapy Diagnosed by FDG PET/CT.

Alabed YZ, Aghayev A, Sakellis C, Van den Abbeele AD.

Clin Nucl Med. 2015 Nov;40(11):e528-9. doi: 10.1097/RLU.0000000000000940.

PMID:
26284765
18.

Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma.

Buchbinder EI, Sosman JA, Lawrence DP, McDermott DF, Ramaiya NH, Van den Abbeele AD, Linette GP, Giobbie-Hurder A, Hodi FS.

Cancer. 2015 Nov 15;121(22):4007-15. doi: 10.1002/cncr.29622. Epub 2015 Aug 11.

19.

Role of FDG-PET/CT in Extramedullary Multiple Myeloma: Correlation of FDG-PET/CT Findings With Clinical Outcome.

Tirumani SH, Sakellis C, Jacene H, Shinagare AB, Munshi NC, Ramaiya NH, Van den Abbeele AD.

Clin Nucl Med. 2016 Jan;41(1):e7-13. doi: 10.1097/RLU.0000000000000902.

PMID:
26252323
20.

Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003).

Lin NU, Guo H, Yap JT, Mayer IA, Falkson CI, Hobday TJ, Dees EC, Richardson AL, Nanda R, Rimawi MF, Ryabin N, Najita JS, Barry WT, Arteaga CL, Wolff AC, Krop IE, Winer EP, Van den Abbeele AD.

J Clin Oncol. 2015 Aug 20;33(24):2623-31. doi: 10.1200/JCO.2014.60.0353. Epub 2015 Jul 13.

21.

Cancer Imaging Training in the 21st Century: An Overview of Where We Are, and Where We Need To Be.

Howard SA, Krajewski KM, Weissman BN, Seltzer SE, Ramaiya NH, Van den Abbeele AD.

J Am Coll Radiol. 2015 Jul;12(7):714-20. doi: 10.1016/j.jacr.2015.03.044.

PMID:
26143565
22.

[(18)F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography of LAPC4-CR Castration-Resistant Prostate Cancer Xenograft Model in Soft Tissue Compartments.

McCall KC, Cheng SC, Huang Y, Kohl NE, Tupper T, Van den Abbeele AD, Zukotynski KA, Sweeney CJ.

Transl Oncol. 2015 Jun;8(3):147-53. doi: 10.1016/j.tranon.2015.03.004.

23.

Advanced High-Grade Serous Ovarian Cancer: Frequency and Timing of Thoracic Metastases and the Implications for Chest Imaging Follow-up.

Shinagare AB, O'Neill AC, Cheng S, Somarouthu B, Tirumani SH, Nishino M, Van den Abbeele AD, Ramaiya NH.

Radiology. 2015 Dec;277(3):733-40. doi: 10.1148/radiol.2015142467. Epub 2015 Jun 5.

PMID:
26053310
24.

Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events.

Kwak JJ, Tirumani SH, Van den Abbeele AD, Koo PJ, Jacene HA.

Radiographics. 2015 Mar-Apr;35(2):424-37. doi: 10.1148/rg.352140121.

PMID:
25763727
25.

Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma.

Zukotynski K, Yap JT, Giobbie-Hurder A, Weber J, Gonzalez R, Gajewski TF, O'Day S, Kim K, Hodi FS, Van den Abbeele AD.

Cancer Imaging. 2014 Nov 12;14:30. doi: 10.1186/s40644-014-0030-0.

26.

A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer.

Courtney KD, Manola JB, Elfiky AA, Ross R, Oh WK, Yap JT, Van den Abbeele AD, Ryan CW, Beer TM, Loda M, Priolo C, Kantoff P, Taplin ME.

Clin Genitourin Cancer. 2015 Apr;13(2):113-23. doi: 10.1016/j.clgc.2014.08.007. Epub 2014 Oct 22.

27.

Voxelwise single-subject analysis of imaging metabolic response to therapy in neuro-oncology.

Guo M, Yap JT, Van den Abbeele AD, Lin NU, Schwartzman A.

Stat. 2014 Jan 1;3(1):172-186.

28.

Bevacizumab plus ipilimumab in patients with metastatic melanoma.

Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, Zeng W, Giobbie-Hurder A, Atkins MB, Ibrahim N, Friedlander P, Flaherty KT, Murphy GF, Rodig S, Velazquez EF, Mihm MC Jr, Russell S, DiPiro PJ, Yap JT, Ramaiya N, Van den Abbeele AD, Gargano M, McDermott D.

Cancer Immunol Res. 2014 Jul;2(7):632-42. doi: 10.1158/2326-6066.CIR-14-0053. Epub 2014 Apr 21. Erratum in: Cancer Immunol Res. 2014 Sep;2(9):923.

29.

10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study.

Krajewski KM, Franchetti Y, Nishino M, Fay AP, Ramaiya N, Van den Abbeele AD, Choueiri TK.

Oncologist. 2014 May;19(5):507-14. doi: 10.1634/theoncologist.2013-0391. Epub 2014 Apr 22.

30.

Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.

Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, Li Y, Cantley LC, Winer E, Arteaga CL.

J Clin Oncol. 2014 Apr 20;32(12):1202-9. doi: 10.1200/JCO.2013.54.0518. Epub 2014 Mar 24.

31.

Metastatic mucosal melanoma: imaging patterns of metastasis and recurrence.

O'Regan K, Breen M, Ramaiya N, Jagannathan J, DiPiro PJ, Hodi FS, Van den Abbeele AD.

Cancer Imaging. 2013 Dec 30;13(4):626-32. doi: 10.1102/1470-7330.2013.0055.

32.

Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria.

Krajewski KM, Nishino M, Franchetti Y, Ramaiya NH, Van den Abbeele AD, Choueiri TK.

Cancer. 2014 Mar 1;120(5):711-21. doi: 10.1002/cncr.28493. Epub 2013 Nov 21.

33.

What radiologists need to know about diagnosis and treatment of inflammatory breast cancer: a multidisciplinary approach.

Yeh ED, Jacene HA, Bellon JR, Nakhlis F, Birdwell RL, Georgian-Smith D, Giess CS, Hirshfield-Bartek J, Overmoyer B, Van den Abbeele AD.

Radiographics. 2013 Nov-Dec;33(7):2003-17. doi: 10.1148/rg.337135503.

PMID:
24224593
34.

End-therapy positron emission tomography for treatment response assessment in follicular lymphoma: a systematic review and meta-analysis.

Pyo J, Won Kim K, Jacene HA, Sakellis CG, Brown JR, Van den Abbeele AD.

Clin Cancer Res. 2013 Dec 1;19(23):6566-77. doi: 10.1158/1078-0432.CCR-13-1511. Epub 2013 Sep 19. Review.

35.

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.

Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE.

J Clin Oncol. 2013 Sep 10;31(26):3182-90. doi: 10.1200/JCO.2012.47.7836. Epub 2013 Jun 17.

36.

Atypical metastases from prostate cancer: 10-year experience at a single institution.

Vinjamoori AH, Jagannathan JP, Shinagare AB, Taplin ME, Oh WK, Van den Abbeele AD, Ramaiya NH.

AJR Am J Roentgenol. 2012 Aug;199(2):367-72. doi: 10.2214/AJR.11.7533.

PMID:
22826398
37.

Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.

George S, Wang Q, Heinrich MC, Corless CL, Zhu M, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Tap WD, Yap JT, Van den Abbeele AD, Manola JB, Solomon SM, Fletcher JA, von Mehren M, Demetri GD.

J Clin Oncol. 2012 Jul 1;30(19):2401-7. doi: 10.1200/JCO.2011.39.9394. Epub 2012 May 21.

38.

Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.

Halasz LM, Jacene HA, Catalano PJ, Van den Abbeele AD, Lacasce A, Mauch PM, Ng AK.

Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):e647-54. doi: 10.1016/j.ijrobp.2012.01.060. Epub 2012 May 18.

PMID:
22607911
39.

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.

Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ, Yu JQ, Vallabhajosula S, Schoder H, English P, Neuberg DS, Martin P, Millenson MM, Ely SA, Courtney R, Shaik N, Wilner KD, Randolph S, Van den Abbeele AD, Chen-Kiang SY, Yap JT, Shapiro GI.

Blood. 2012 May 17;119(20):4597-607. doi: 10.1182/blood-2011-10-388298. Epub 2012 Mar 1.

40.

ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression.

Van den Abbeele AD, Gatsonis C, de Vries DJ, Melenevsky Y, Szot-Barnes A, Yap JT, Godwin AK, Rink L, Huang M, Blevins M, Sicks J, Eisenberg B, Siegel BA.

J Nucl Med. 2012 Apr;53(4):567-74. doi: 10.2967/jnumed.111.094425. Epub 2012 Mar 1.

41.

Hereditary cancer syndromes: a radiologist's perspective.

Shinagare AB, Giardino AA, Jagannathan JP, Van den Abbeele AD, Ramaiya NH.

AJR Am J Roentgenol. 2011 Dec;197(6):W1001-7. doi: 10.2214/AJR.11.6465. Review.

PMID:
22109313
42.

Imaging in renal cell carcinoma.

Krajewski KM, Giardino AA, Zukotynski K, Van den Abbeele AD, Pedrosa I.

Hematol Oncol Clin North Am. 2011 Aug;25(4):687-715. doi: 10.1016/j.hoc.2011.04.005. Review.

PMID:
21763963
43.

Urothelial cancers of the upper urinary tract: metastatic pattern and its correlation with tumor histopathology and location.

Shinagare AB, Fennessy FM, Ramaiya NH, Jagannathan JP, Taplin ME, Van den Abbeele AD.

J Comput Assist Tomogr. 2011 Mar-Apr;35(2):217-22. doi: 10.1097/RCT.0b013e31820d7a37.

PMID:
21412093
44.

Incidence of pulmonary embolism in oncologic outpatients at a tertiary cancer center.

Shinagare AB, Guo M, Hatabu H, Krajewski KM, Andriole K, Van den Abbeele AD, DiPiro PJ, Nishino M.

Cancer. 2011 Aug 15;117(16):3860-6. doi: 10.1002/cncr.25941. Epub 2011 Feb 11.

45.

Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.

Krajewski KM, Guo M, Van den Abbeele AD, Yap J, Ramaiya N, Jagannathan J, Heng DY, Atkins MB, McDermott DF, Schutz FA, Pedrosa I, Choueiri TK.

Eur Urol. 2011 May;59(5):856-62. doi: 10.1016/j.eururo.2011.01.038. Epub 2011 Feb 1.

PMID:
21306819
46.

Imaging of lung cancer in the era of molecular medicine.

Nishino M, Jackman DM, Hatabu H, Jänne PA, Johnson BE, Van den Abbeele AD.

Acad Radiol. 2011 Apr;18(4):424-36. doi: 10.1016/j.acra.2010.10.020. Epub 2011 Jan 28. Review.

47.

Metastatic pattern of bladder cancer: correlation with the characteristics of the primary tumor.

Shinagare AB, Ramaiya NH, Jagannathan JP, Fennessy FM, Taplin ME, Van den Abbeele AD.

AJR Am J Roentgenol. 2011 Jan;196(1):117-22. doi: 10.2214/AJR.10.5036.

PMID:
21178055
48.

CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool.

Nishino M, Guo M, Jackman DM, DiPiro PJ, Yap JT, Ho TK, Hatabu H, Jänne PA, Van den Abbeele AD, Johnson BE.

Acad Radiol. 2011 Jan;18(1):54-62. doi: 10.1016/j.acra.2010.08.021. Epub 2010 Oct 30.

49.

Imaging of extraosseous myeloma: CT, PET/CT, and MRI features.

Hall MN, Jagannathan JP, Ramaiya NH, Shinagare AB, Van den Abbeele AD.

AJR Am J Roentgenol. 2010 Nov;195(5):1057-65. doi: 10.2214/AJR.10.4384. Review.

PMID:
20966307
50.

Adult extragonadal germ cell tumors.

Shinagare AB, Jagannathan JP, Ramaiya NH, Hall MN, Van den Abbeele AD.

AJR Am J Roentgenol. 2010 Oct;195(4):W274-80. doi: 10.2214/AJR.09.4103.

PMID:
20858789

Supplemental Content

Loading ...
Support Center